Peptide Therapeutics Industry to Reach USD 117.4 Billion by 2034 at a 10.8% of CAGR

Peptide Therapeutics Market

The global peptide therapeutics market is on a strong growth trajectory, with sales projected to rise from USD 42.1 billion in 2024 to an impressive USD 117.4 billion by 2034, registering a robust compound annual growth rate (CAGR) of 10.8% during the forecast period. In 2023, the market generated USD 38.0 billion in revenue, showcasing the increasing importance of peptide-based treatments in modern medicine.

Peptide therapeutics are becoming a cornerstone in treating a wide range of diseases, including cancer, metabolic disorders, and infectious diseases, due to their high specificity, efficacy, and safety profiles. The growing interest in biologics and the shift toward precision medicine are driving the adoption of peptide therapeutics, making them an integral part of pharmaceutical innovations.

The rapid pace of technological advancements, including peptide synthesis, delivery systems, and novel formulations, is further accelerating market growth. Additionally, the rising prevalence of chronic diseases, coupled with increased investment in biopharmaceutical research, is expected to sustain the high demand for peptide therapeutics over the next decade.

A Detailed Full Report – https://www.futuremarketinsights.com/reports/peptide-therapeutics-market

Key Takeaways:

• Market Growth: Sales expected to increase from USD 42.1 billion in 2024 to USD 117.4 billion by 2034, with a CAGR of 10.8%.
• Disease Applications: Peptide therapeutics are gaining traction for their role in treating cancer, metabolic disorders, and other chronic conditions.
• Technological Advancements: Innovations in peptide synthesis and delivery systems are driving growth and enhancing therapeutic outcomes.
• Healthcare Trends: Rising adoption of precision medicine and biologics is further fueling market demand.

Key Industry Highlights

Cancer Prevalence Driving the Peptide Therapeutics Market

The escalating global prevalence of cancer is a major driving force behind the growth of the peptide therapeutics market. In 2022, the World Health Organization (WHO) reported approximately 20 million new cancer cases and 9.7 million cancer-related deaths worldwide.

This alarming increase in cancer incidence emphasizes the pressing need for advanced and effective treatment options to address the growing burden of this life-threatening disease.

However, in recent times, the peptide-based therapies have been a significant promise in the treatment of cancer. While compared to other treatment modalities, they can target the cancer cells without blemishing the healthy tissues.

Less side effects tend to manifest with peptide therapy compared with standard treatments. Increased acceptance of the benefits rendered by such highly specified and efficient therapy has been borne out by the rise in cancer incidences worldwide.

There is also the opportunity for increased utilization of peptide therapy, as people are beginning to see these novel cancer treatment options. With ever-increasing cancer prevalence, the advancements in peptide-based therapies are poised to grow significantly, thus entrenching this segment in the arena of global anti-cancer ever fought.

Competitive Landscape

The peptide therapeutics market is highly competitive, with numerous manufacturers striving to innovate and enhance their product offerings. Leading producers are focusing on international expansion to boost revenue and establish a broader sales presence in developing markets.

This is often achieved through acquisitions of regional players. Key strategies adopted by manufacturers include partnerships, agreements, product launches, sponsorship of research initiatives, and strategic collaborations, all aimed at strengthening their market position and driving sales.

Recent Industry Developments in Peptide Therapeutics Market:

• In May 2022, Bristol Myers Squibb and LOTTE Corporation announced that LOTTE would acquire Bristol Myers Squibb’s production facility in East Syracuse, New York. This facility is expected to serve as the USA base for LOTTE’s new biologics CDMO operations.
• In May 2021, ISSAR Pharmaceuticals revealed plans to license its peptide-based novel chemical entities. These entities, protected by a USA patent and supported by a pre-IND file, are designed to address neglected healthcare needs, making treatments more accessible and affordable for better health outcomes.

Key Players of Peptide Therapeutics Industry

• Eli Lilly and Company
• Ipsen S.A
• AstraZeneca plc Merck & Co. Inc
• Teva Pharmaceutical Industries Ltd.
• Novo Nordisk A/S

Key Segments of Peptide Therapeutics Industry

By Application:

In terms of application, the industry is divided into cancer, cardiovascular diseases, central nervous systems, metabolic disorders, infections, hematological disorders, gastrointestinal disorders, dermatology, respiratory disorders, acromegaly, and other applications.

By Route of Administration:

In terms of route of administration, the industry is segregated into parenteral route of administration, mucosal route of administration, oral route of administration, and transdermal of route administration.

By Drug Type:

In terms of drug type, the industry is divided into branded drugs, generic/biosimilar drugs.

By Region:

Key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle East and Africa (MEA) have been covered in the report.

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube